Clinical Trial: A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205315) titled 'A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies' on Sept. 25.

Brief Summary: The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Hematological Malignancy (Leukemia- Lymphoma)

Intervention: BIOLOGICAL: GT801 Injection

GT801 Injection

Recruitment Status: RECRUITING

Sponsor: Grit Biotechnology

Disclaimer: Curated by HT Syndicat...